GLP-1 Agonists and Blood Pressure: A Review of the Evidence

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men

(2015) Ali Asmar et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

DPP4 in Cardiometabolic Disease: Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition

(2015) J. Zhong et al.   CIRCULATION RESEARCH

Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors

(2015) Jixin Zhong et al.   Clinical Lipidology

Association of Cardiometabolic Multimorbidity With Mortality

(2015) Emanuele Di Angelantonio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients

(2014) Chun-Jun Li et al.   Cardiovascular Diabetology

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes

(2014) Julie A. Lovshin et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects

(2014) Laurence G. Trahair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials

(2014) Vivian A. Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Postprandial Hypotension: A Systematic Review

(2014) Laurence G. Trahair et al.   Journal of the American Medical Directors Association

Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm

(2014) Jessica K. Devin et al.   Journal of the American Heart Association

Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression

(2013) M. Katout et al.   AMERICAN JOURNAL OF HYPERTENSION

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

(2013) B. Wang et al.   DIABETES OBESITY & METABOLISM

Comparison of postprandial blood pressure reduction in the elderly by different body position

(2013) Jung Tae Son et al.   GERIATRIC NURSING

Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men

(2013) Jeppe Skov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

(2013) Minsuk Kim et al.   NATURE MEDICINE

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

(2013) Marcel H. A. Muskiet et al.   Nature Reviews Nephrology

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

(2013) Jeppe Skov et al.   Endocrine Connections

GLP-1 and cardioprotection: from bench to bedside

(2012) S. Ravassa et al.   CARDIOVASCULAR RESEARCH

Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome

(2012) M. Tesauro et al.   DIABETES CARE

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

(2012) J. Rosenstock et al.   DIABETES CARE

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

(2012) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

Cardiovascular Biology of the Incretin System

(2012) John R. Ussher et al.   ENDOCRINE REVIEWS

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC- 

(2011) C. Cabou et al.   DIABETES

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

(2011) S. Madsbad et al.   DIABETES OBESITY & METABOLISM

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

(2011) Zubair Shah et al.   VASCULAR PHARMACOLOGY

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

(2010) Que Liu et al.   Cardiovascular Diabetology

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets

(2010) R. Lupi et al.   REGULATORY PEPTIDES

The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent

(2010) Brian L. Furman   TOXICON

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

(2009) Kunio Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

(2009) B. Gallwitz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

(2009) Kevin D. Laugero et al.   Metabolic Syndrome and Related Disorders

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

(2008) Adil E. Bharucha et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

(2008) C. Cabou et al.   DIABETES

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET